echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Medicine's "Pregabalin Sustained-Release Tablets" Approved for Listing in China

    Hengrui Medicine's "Pregabalin Sustained-Release Tablets" Approved for Listing in China

    • Last Update: 2021-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    ArticleMedicine Guanlan

    Today, China's National Food and Drug Administration (NMPA) announced that the pregabalin sustained-release tablets declared by Hengrui Medicine have been approved for listing in China
    Public information shows that pregabalin is an analgesic, and Hengrui Medicine has applied for pregabalin sustained-release tablets, which belong to the 2.
    2 new drugs


    Screenshot source: NMPA official website

    Pregabalin is an analogue of the neurotransmitter γ-aminobutyric acid (GABA).
    The original drug was developed by Pfizer

    It can bind to and inhibit the α2-σ subunit protein of voltage-dependent calcium channels, reduce the depolarization of nerve endings and calcium ion influx, thereby inhibiting the release of excitatory neurotransmitters such as L-glutamate

    The release of these excitatory neurotransmitters is associated with convulsions, pain and anxiety


    The original drug pregabalin has been approved for multiple indications worldwide, including diabetic peripheral neuropathy, post-herpetic neuralgia, fibromyalgia syndrome, neuralgia caused by spinal cord injury, and as an adjuvant therapy for adult patients Part of epileptic seizures and many other diseases
    In China, Pfizer's Pregabalin capsules have been approved for marketing

    In addition, a number of generic pregabalin capsules and pregabalin oral solutions have been approved


    The dosage form declared by Hengrui Medicine is pregabalin sustained-release tablets
    According to the information from the Chinese drug clinical trial registration and information disclosure platform, Hengrui Medicine has registered a number of phase 1 clinical studies of pregabalin sustained-release tablets, involving indications including post-herpetic neuralgia, fibromyalgia, and postoperative analgesia , fibromyalgia and so on

    The approval of the drug will bring more treatment options to patients


    Reference materials:

    [1] On September 28, 2021, the drug approval document pending information is released.
    Retrieved Sep 28, 2021, from https://

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.